In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Twenty five countries have reported outbreaks, including newly affected Sierra Leone where infections are surging.

Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

Summer hasn't officially started, but already smoke from wildfires across the Prairie provinces has descended on us, sparking ...

A substantial burden of hospitalizations for PIV-associated ARI was observed among pediatric patients in the United States.

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal ...